Trial Information

Summary: A Randomized Phase III Trial of Cetuximab, Bevacizumab and Biweekly Infusional 5-FU/Leucovorin (FOLF-CB) versus Oxaliplatin, Bevacizumab, and Biweekly Infusional 5-FU/Leucovorin (Bev-FOLFOX) in First-line Treatment of Metastatic Colorectal Cancer

Patient Inclusion Criteria

  • Colorectal cancer that has spread to other parts of the body.

Patient Exclusion Criteria

  • Previous treatment for metastatic colorectal cancer, such as Oxaliplatin or Bevacizumab.

Contact:

Raquel Beauchamp, Research Study Coordinator
Gainesville Hematology/ Oncology Associates
1147 N.W. 64th Terrace
Gainesville, FL 32605
Telephone: 352-332-3900
Fax: 352-331-3802
Email:

Profile Page: Gainesville Hematology/ Oncology Associates, Gainesville, FL

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:46:17 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA